


Ask a doctor about a prescription for MIRTAZAPINE TEVA-RATIO 45 mg FILM-COATED TABLETS
Package Leaflet:information for the user
Mirtazapine Teva-ratio 45 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
5 Storage of Mirtazapine Teva-ratio
Mirtazapine Teva-ratio contains the active substance mirtazapine and belongs to the group of medicines called antidepressants.
Mirtazapine is used to treat depression in adults.
It may take 1 to 2 weeks before mirtazapine starts to work. After 2 to 4 weeks you may start to feel better. You should consult your doctor if you do not feel better or if you feel worse after 2 to 4 weeks.
For more information see section 3 “When you can expect to feel better”.
Do not take Mirtazapine Teva-ratio
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to take mirtazapine.
DO NOT TAKE OR CONSULT YOUR DOCTOR BEFORE TAKINGmirtazapine:
If you have ever suffered from a severe skin rash or skin peeling, blisters or sores in the mouthafter taking mirtazapine or other medicines.
Children and adolescents
Mirtazapine should not normally be used for the treatment of children and adolescents under 18 years. Also, you should know that patients under 18 are at an increased risk of side effects such as suicide attempt, suicidal thoughts and hostility (mainly aggression, confrontation and anger) when they take this class of medicines. However, your doctor may prescribe mirtazapine for patients under 18 when he decides that it is the best for the patient. If your doctor has prescribed mirtazapine to a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms mentioned above appear or worsen in patients under 18 who are taking mirtazapine. Furthermore, the long-term safety effects on growth, maturation, and cognitive and behavioral development in this age group have not yet been established. Additionally, a significant weight gain has been observed in this age group more frequently when treated with mirtazapine compared to adults.
Suicidal thoughts and worsening of depression
If you are depressed you may sometimes have thoughts of harming or killing yourself. These thoughts may be worse when you first start taking antidepressants, as these medicines take a few weeks to start working, usually around two weeks or sometimes longer.
You may be more likely to think this way if:
If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.
It might be helpful to tell a relative or close friend that you are depressed and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.
Also, be extra careful with mirtazapine
If you have or have ever had any of the following conditions.
Tell your doctor about these conditions before taking Mirtazapine Teva, if you have not already done so:
Stop taking mirtazapine and contact your doctor immediately to have a blood test.
In rare cases, these symptoms can be signs of changes in blood cell production in the bone marrow. Although rare, these symptoms usually occur within 4-6 weeks of treatment.
Severe skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of mirtazapine. Stop taking mirtazapine and seek medical attention immediately if you notice any of the symptoms described in section 4 related to these severe skin reactions.
If you have ever suffered from severe skin reactions, you should never take mirtazapine again.
Other medicines and Mirtazapine Teva-ratio
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not takemirtazapine with:
Examples of MAOIs are moclobemide, tranylcypromine (both are antidepressants) and selegiline (for Parkinson's disease).
Be careful ifyou take mirtazapine with:
If taken with mirtazapine, these medicines may reduce the amount of mirtazapine in your blood. Inform your doctor if you are taking these medicines. It may be necessary to increase the dose of mirtazapine or reduce it again when you stop taking these medicines.
TakingMirtazapine Teva-ratio with foodand alcohol
You may feel drowsy if you drink alcohol while you are taking mirtazapine. It is recommended not to drink alcohol.
You can take mirtazapine with or without food.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Limited experience with mirtazapine administration to pregnant women does not indicate an increased risk. However, caution should be exercised when used during pregnancy. If you use mirtazapine until or shortly before birth, your baby will be checked for possible adverse effects.
Make sure your midwife and/or doctor know that you are taking mirtazapine. When similar medicines (SSRIs) are taken during pregnancy, they can increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), which makes the baby breathe faster and turn blue. These symptoms usually start during the first 24 hours after the baby is born. If this happens to your baby, you should contact your midwife and/or doctor immediately.
Breast-feeding
Ask your doctor whether you can breast-feed while taking mirtazapine.
Driving and using machines
Mirtazapine may affect your concentration or alertness. Make sure your abilities are not affected before driving or using machinery. If your doctor has prescribed mirtazapine to a patient under 18, make sure that concentration and alertness are not affected before cycling (for example).
Mirtazapine Teva-ratio contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Mirtazapine Teva-ratio contains sodium
This medicine contains less than 1mmol of sodium (23 mg) per film-coated tablet; this is essentially “sodium-free”.
Take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
The recommended initial dose is 15 or 30 mg per day. Your doctor may recommend that you increase the dose after a few days to the amount that is best for you (between 15 and 45 mg per day). The dose is usually the same for all ages. However, if you are an elderly person or if you have kidney or liver disease, your doctor may change the dose.
When to take Mirtazapine Teva-ratio
Take mirtazapine at the same time each day. It is best to take the dose of mirtazapine once before going to bed. However, your doctor may recommend that you divide your dose of mirtazapine in the morning and before going to bed. The highest dose should be taken before going to bed. The tablets are taken orally. Take the prescribed dose of mirtazapine without chewing, with water or juice.
When you can expect to feel better
Mirtazapine will usually start to work after 1 to 2 weeks and after 2 to 4 weeks you may start to feel better.
It is important that during the first few weeks of treatment you talk to your doctor about the effects of mirtazapine:
→ between 2 and 4 weeks after you start taking mirtazapine, talk to your doctor about how this medicine has affected you.
If you do not feel better, your doctor may prescribe a higher dose. In that case, talk to your doctor again after another 2-4 weeks.
Normally, you will need to take mirtazapine until the symptoms of depression have disappeared for 4-6 months.
If you take more Mirtazapine Teva-ratio than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you or someone else has taken too much mirtazapine, contact a doctor immediately. The most likely symptoms of a mirtazapine overdose (without other medicines or alcohol) are drowsiness, disorientation and palpitations.The symptoms of a possible overdose may include changes in your heart rhythm (fast, irregular heartbeat) and/or fainting, which could be symptoms of a potentially life-threatening condition known as Torsade de Pointes.
If you forget to take Mirtazapine Teva-ratio
If you have to take your dose once a day
If you have to take your dose twice a day
If you stop taking Mirtazapine Teva-ratio
Only stop taking mirtazapine if you have talked to your doctor.
If you stop taking it too soon, your depression may come back. When you are feeling better, talk to your doctor. Your doctor will decide when you can stop treatment.
Do not stop taking mirtazapine abruptly, even if your depression has disappeared. If you stop taking mirtazapine abruptly, you may feel unwell, dizzy, agitated or anxious and have headaches. These symptoms can be avoided by gradually stopping treatment. Your doctor will tell you how to reduce the dose gradually.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If you experience any of the following serious adverse effects, stop taking mirtazapine and inform your doctor immediately.
Uncommon(may affect up to 1 in 100 patients):
Rare (may affect up to 1 in 1,000 patients):
Frequency not known(cannot be estimated from available data):
Other possible adverse effects with mirtazapine are:
Very common(may affect more than 1 in 10 patients):
Common (may affect up to 1 in 10 patients):
Uncommon(may affect up to 1 in 100 patients):
Rare(may affect up to 1 in 1,000 patients):
Frequency not known(cannot be estimated from available data):
Additional adverse effects in children and adolescents
In children under 18 years of age, the following adverse effects were frequently observed in clinical trials: significant weight gain, urticaria, and increased triglycerides in the blood.
Reporting adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiration date shown on the box and blister pack after EXP or CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Mirtazapine Teva-ratio
Mirtazapine Teva-ratio 45 mg film-coated tablets EFG contain 45 mg of mirtazapine per film-coated tablet.
Core of the tablet: lactose monohydrate, pregelatinized corn starch, anhydrous colloidal silica (E551), sodium croscarmellose (E468), magnesium stearate (E470b).
Coating of the tablet: hypromellose (E464), macrogol 8000 (E1521), titanium dioxide (E171), talc.
Appearance of the product and package contents
Mirtazapine Teva-ratio are film-coated tablets.
White, oval, biconvex film-coated tablets, 14.5 x 7.5 mm in diameter. Marked with "I" on one face.
Package sizes:
20, 30, 50, and 100 tablets in blister packs.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Teva B.V.
Swensweg 5,
2031GA Haarlem,
Netherlands
Manufacturer:
Actavis Ltd
BLB 015, BLB 016,
Bulebel Industrial Estate
ZTN3000 Zejtun
Malta
or
Balkanpharma-Dupnitsa AD
3 Samokovsko Shosse Str.
Dupnitsa, 2600
Bulgaria
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Teva Pharma, S.L.U.
C/ Anabel Segura 11, Edificio Albatros B, 1ª planta
28108 Alcobendas (Madrid)
Spain
This medicine is authorized in the member states of the European Economic Area
Austria Mirtabene-ratiopharm GmbH 45 mg Filmtabletten
Germany Mirtazapin-ratiopharm 45 mg Filmtabletten
Denmark Mirtazapin Teva B.V.
Spain Mirtazapina Teva-ratio 45 mg film-coated tablets EFG
Finland Mirtazapin ratiopharm 45 mg kalvopäällysteiset tabletit
Luxembourg Mirtazapin-ratiopharm 45 mg Filmtabletten
Portugal Mirtazapina ratiopharm
Date of the last revision of thisprospectus:March 2023
Other sources of information
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
You can access detailed and updated information about this medicine by scanning the QR code included in the packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/88860/P_88860.html
The average price of MIRTAZAPINE TEVA-RATIO 45 mg FILM-COATED TABLETS in November, 2025 is around 25.57 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MIRTAZAPINE TEVA-RATIO 45 mg FILM-COATED TABLETS – subject to medical assessment and local rules.